BTIG increased its price target for Cullinan Therapeutics to $40, reflecting a potential 93% upside from the current stock price of around $20.73. This upgrade follows successful Phase 3 trial results for zipalertinib, a treatment for non-small cell lung cancer, which showed a significant 6-month improvement in progression-free survival when combined with chemotherapy. The positive trial outcome boosts confidence in Cullinan's cancer therapy pipeline and may drive future stock gains. The company shared these results at a recent oncology conference and investor event.
Cullinan Therapeutics is noted for its recent positive Phase 3 lung cancer trial results. For readers following the health sector, here is Pluang's market snapshot as of Sep 15, 2026 00:02 WIB: Among 91 priced US health stocks, 76 advanced and 14 declined. Notable movers include AMWL at USD 13.65 (+5.04%), DNA at USD 7.09 (+5.04%), and TDOC at USD 6.47 (+5.03%).
Parex Resources announced its Q3 2026 average production reached 83,259 barrels of oil equivalent per day, driven by exploration success and a partnership with Ecopetrol. The company reaffirmed its H2 2026 production guidance of 82,000 to 91,000 boe/...
EnergyLIB is entering a new growth phase following a proposed strategic investment by Nasdaq-listed Cheche Group in its residential solar-plus-storage business, Long Way Fortune. This investment supports Cheche Group's expansion into the global resid...
Copa Holdings announced preliminary passenger traffic data for September 2026, showing a 17.1% increase in revenue passenger miles (RPM) to 2,674.4 million and a 15.7% rise in available seat miles (ASM) to 3,041.0 million compared to September 2025. ...
Bitdeer Technologies Group has issued a notice asking journalists and readers to disregard a previously released news statement about Bitdeer AI securing 60MW at its Cyberjaya, Malaysia facility and reaching 95% of its 350MW target capacity. This ret...
SpaceX is expanding its AI infrastructure to support its rocket launches, Starlink satellite network, and future AI growth plans. Analysts show mixed but generally positive sentiment, with Morgan Stanley maintaining a Buy rating and a $300 price targ...
